Abstract:The inflammation is the protective response of the body against various harmful stimuli; however, the aberrant and inappropriate activation tends to become harmful. The acute inflammatory response tends to resolved once the offending agent is subside but this acute response becomes chronic in nature when the body is unable to successfully neutralized the noxious stimuli. This chronic inflammatory microenvironment is associated with the release of various pro-inflammatory and oncogenic mediators such as nitric oxide (NO), cytokines [IL-1β, IL-2, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α)], growth factor, and chemokines. These mediators make the inflammatory microenvironment more vulnerable toward tumorigenesis. The pro-inflammatory mediators released during the chronic inflammation tends to induce several molecular signaling cascades such as nuclear factor kappa B, MAPKinase, nuclear factor erythroid 2-related factor 2, phosphoinositide-3-kinase, Janus kinases/STAT, Wnt/B-catenin, and cyclic AMP response element binding protein. The immune system and its components have a pleiotropic effect on inflammation and cancer progression. Immune components such as T cells, natural killer cells, macrophages, and neutrophils either inhibit or enhance tumor initiation depending on the type of tumor and immune cells involved. Tumor-associated macrophages and tumor-associated neutrophils are pro-tumorigenic cells highly prevalent in inflammation-mediated tumors. Similarly, presence of T regulatory (Treg) cells in an inflammatory and tumor setting suppresses the immune system, thus paving the way for oncogenesis. However, Treg cells also inhibit autoimmune inflammation. By contrast, cytotoxic T cells and T helper cells confer antitumor immunity and are associated with better prognosis in patients with cancer. Cytotoxic T cells inflict a direct cytotoxic effect on cells expressing oncogenic markers. Currently, several anti-inflammatory and antitumor therapies are under trials in which these immune cells are exploited. Adoptive cell transfer composed of tumor-infiltrating lymphocytes has been tried for the treatment of tumors after their ex vivo expansion. Mediators released by cells in a tumorigenic and inflammatory microenvironment cross talk with nearby cells, either promoting or inhibiting inflammation and cancer. Recently, several cytokine-based therapies are either being developed or are under trial to treat such types of manifestations. Monoclonal antibodies directed against TNF-α, VEGF, and IL-6 has shown promising results to ameliorate inflammation and cancer, while direct administration of IL-2 has been shown to cause tumor regression.

Clampdown of inflammation in aging and anticancer therapies by limiting upregulation and activation of GPCR, CXCR4

Cell Cycle Checkpoints Cooperate to Suppress DNA- and RNA-Associated Molecular Pattern Recognition and Anti-Tumor Immune Responses

IFI16, an amplifier of DNA-damage response: Role in cellular senescence and aging-associated inflammatory diseases

CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response

Cytoplasmic chromatin triggers inflammation in senescence and cancer

Regulation of cGAS-STING signalling in cancer: Approach for combination therapy

CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model: CB1 antagonists for nephropathy

Inflammation-Induced Tumorigenesis: Diminished Noncanonical NF-κB Signaling is Associated with Pathogenesis of Colitis-associated Colorectal Cancer

Research Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response

Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling

Mitochondria-to-nucleus retrograde signaling drives formation of cytoplasmic chromatin and inflammation in senescence

Cgas and Cancer Therapy: a Double-Edged Sword

OPPOSING EFFECTS OF CB1 AND CB2 RECEPTORS ON INFLAMMATION, OXIDATIVE STRESS, AND CELL DEATH IN NEPROPATHY

A mitochondria-regulated p53-CCF circuit integrates genome integrity with inflammation

cGAS-STING signalling regulates microglial chemotaxis in genome instability

Oncogenic pathways activated by pro-inflammatory cytokines promote mutant p53 stability: clue for novel anticancer therapies

CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5

P2Y2 purinergic receptor and DNA sensor cGAS dictate ionizing radiation-mediated proinflammatory macrophage activation

A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses

DNA damage and repair in age-related inflammation

Immunological Approaches Towards Cancer and Inflammation: A Cross Talk